Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMRJF2Q)

Drug Name
Citatuzumab bogatox Drug Info
Synonyms VB6-845; Antibody therapeutic (ovary tumor), Viventia; Ovary cancer therapeutic (antibody), Viventia; Anti-EpCAM-bouganin conjugate (anticancer), Viventia
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMRJF2Q

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor-associated calcium signal transducer 1 (EPCAM) TTZ8WH4 EPCAM_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tumor-associated calcium signal transducer 1 (EPCAM) DTT EPCAM 4.307 10.904 9.628 10.804
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tumor-associated calcium signal transducer 1 (EPCAM) DTT EPCAM 5.99E-02 -0.11 -1.11
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00481936) Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin. U.S. National Institutes of Health.
2 Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm. 2012 Nov;27(9):582-92.